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Abstract The klotho gene may be involved in the aging
process. Klotho is a coactivator of FGF23, a regulator of
phosphate and vitamin D metabolism. It has also been
reported to be downregulated in insulin resistance syn-
dromes and paradoxically to directly inhibit IGF-1 and
insulin signaling. Our aim was to study klotho’s regulation
and effects on insulin and IGF-1 signaling to unravel this
paradox. We studied klotho tissue distribution and expres-
sion by quantitative real-time polymerase chain reaction
and Western blotting in obese Zucker rats and high-fat fed
Wistar rats, two models of insulin resistance. Klotho was
expressed in kidneys but at much lower levels (<1.5%) in
liver, muscle, brain, and adipose tissue. There were no
significant differences between insulin resistant and control
animals. We next produced human recombinant soluble
klotho protein (KLEC) and studied its effects on insulin and
IGF-1 signaling in cultured cells. In HEK293 cells, FGF23
signaling (judged by FRS2-α and ERK1/2 phosphoryla-
tion) was activated by conditioned media from KLEC-
producing cells (CM-KLEC); however, IGF-1 signaling
was unaffected. CM-KLEC did not inhibit IGF-1 and
insulin signaling in L6 and Hep G2 cells, as judged by
Akt and ERK1/2 phosphorylation. We conclude that
decreased klotho expression is not a general feature of
rodent models of insulin resistance. Further, the soluble
klotho protein does not inhibit IGF-1 and/or insulin
signaling in HEK293, L6, and HepG2 cells, arguing against
a direct role of klotho in insulin signaling. However, the
hypothesis that klotho indirectly regulates insulin sensitiv-
ity via FGF23 activation remains to be investigated.
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Introduction
The klotho gene has been proposed as a regulator of the
aging process. Homozygous (−/−) klotho-deficient mice
(“klotho mice”) have a reduced life span and display many
features resembling human aging [1]. Conversely, an
extended life span was demonstrated in transgenic mice
engineered to express klotho in a ubiquitous manner [2].
Several cellular mechanisms underlying klotho’s antiaging
effects have been proposed. The klotho gene encodes a
130-kD (1,014 amino acids) type 1 membrane protein,
expressed mainly in mouse kidney and possibly at lower
levels in other organs including the brain. The soluble
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extracellular domain is also found in the circulation,
presumably after shedding from renal cells, and may act
as an endocrine factor [3, 4]. Klotho is a coactivator of
FGF23, a hormone produced by bone-forming cells [5] that
enhances renal phosphate excretion and inhibits vitamin D
1α-hydroxylation. Klotho converts the FGF receptor 1
(FGFR1, more specifically the FGFR1beta(III)c isoform)
from a FGF2 receptor to a FGF23 receptor [6, 7]. FGF23
gain-of-function mutations underlie congenital hypophos-
phatemic rickets, a rare autosomal dominant disease [8, 9].
FGF23 knockout mice bear striking similarities with klotho
mice [7, 10]. Shared features include growth retardation
and soft tissue calcifications, which are in large part
accounted for by high 1α-hydroxylase activity and elevated
vitamin D levels [11]. Studies in klotho mice overexpress-
ing FGF23 or klotho/FGF23 double knockout mice indicate
an absolute requirement for klotho in FGF23 activity in
vivo [12, 13]. These data indicate that inactivation of
FGF23 signaling in renal tubular cells and the consequent
abnormalities in calcium, phosphate, and vitamin D
metabolism account for most, if not all, features of the
aging phenotype observed in klotho mice. However, FGF23
overexpression is expected to induce a disease state [14]; it
is, therefore, unlikely that klotho mediates increased
longevity via FGF23 coactivation.
Several studies have indicated that klotho induces insulin
resistance. Klotho mice display adipose tissue atrophy,
increased insulin sensitivity, pancreatic islet atrophy, and
hypoglycemia [1, 15]. Conversely, klotho transgenic mice
with increased longevity are characterized by insulin
resistance, judged from the glucose/insulin ratio and hyper-
insulinemic euglycemic clamps. These abnormalities are
observed in males only. However, mice from both genders
are resistant to the hypoglycemic effect of insulin and IGF-1.
The administration of murine soluble recombinant klotho
(952 residue extracellular domain) induces an increase in
blood glucose levels and a decreased hypoglycemic
response to insulin in both genders. In cultured L6
myocytes, recombinant klotho inhibits insulin- and IGF-
1-induced glucose transport and tyrosine phosphorylation
of the insulin receptor (IR) and IRS-1. Klotho-induced
insulin resistance is not explained by reduced insulin or
IGF-1 binding to their receptors [2]. These in vitro
experiments suggest that klotho may have direct effects
on insulin signaling, independent of FGF23. Other studies
have suggested that the soluble klotho protein confers
resistance to insulin-induced oxidative stress via activation
of FoxO transcription factors [16]. Klotho effects on insulin
signaling or oxidative stress resistance may occur either via
klotho expression in tissues involved in carbohydrate
metabolism or as a hormone, after release of the klotho
extracellular domain from renal tubular cells into the
circulation [3].
The finding that klotho induces both insulin resistance
and increased longevity is hard to reconcile with the notion
that insulin resistance plays a central role in the metabolic
syndrome, a cluster of cardiovascular risk factors. In the
Otsuka–Long–Evans–Tokushima fatty rat (OLETF), an
animal model of the metabolic syndrome (combining
obesity, diabetes, hypertension, and dyslipidemia), a de-
creased renal expression of klotho is observed although
these animals display insulin resistance. Decreased klotho
expression is corrected by treatment with the insulin
sensitizer troglitazone [17]. In this model, gene therapy
with klotho led to the correction of hypertension and of
endothelium-dependent (ED) relaxation, possibly via im-
provement in insulin resistance [18]. Klotho mice display
impaired ED relaxation which is corrected by parabiosis
with wild-type mice, compatible with the notion that
circulating klotho regulates ED relaxation [19]. These
preliminary studies suggest that klotho may (at least in
part) correct the abnormalities which constitute the meta-
bolic syndrome.
In a first step to clarify these contradictory findings, we
undertook a study to determine the tissue distribution of
klotho in a wide range of tissues, using quantitative real-
time polymerase chain reaction (RT-PCR). We also inves-
tigated whether klotho expression is regulated in two
models of insulin resistance, the Zucker rat and high-fat
feeding in Wistar rats, and whether it is influenced by the
insulin sensitizer pioglitazone. We also studied the effects
of the klotho soluble protein on insulin signaling in vitro.
Methods
Reagents
Myc antibody was from Invitrogen (Basel, Switzerland),
and all others antibodies were from Cell Signaling
(Danvers, MA, USA): Phospho-FRS2-α Tyr-196
(CS#3864), Phospho p42/44 (CS#9106), P42/44
(CS#9102), Akt (CS#9272), and Phospho-Akt Ser-473
(CS#9271). FGF23 was from R&D systems (Minneapolis,
MN, USA; 2604-FG). Pioglitazone was from Takeda
pharmaceuticals.
Animal studies
Male obese Zucker (fa/fa) rats and lean controls (FA/?) rats
were purchased from Charles River laboratories (L’Arbresle,
France). They were housed under controlled temperature
(22°C) and lighting (light on: 7 a.m.–7 p.m.). A first
series of animals (five obese and five lean) was kept on a
standard diet (RMI, SDS, Essex, UK) and sacrificed at age
10 weeks. A second group of ten obese 8-week-old rats was
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treated with vehicle (n=4) or pioglitazone (n=6) for
4 weeks. They had ad libitum access to water and to a
standard chow diet (consisting by energy: 52.8% carbohy-
drates, 9.2% fat, 38% protein (diet 3200; Kliba)). Pioglita-
zone was incorporated in the diet (0.24 g/kg). Insulin
resistance was assessed by the homeostasis model of insulin
resistance (HOMA-IR) [20]. The full metabolic character-
ization of these animals has previously been reported [21].
Eight-week-old male Wistar rats were purchased from
Charles River (L’Arbresle, France). They were housed under
controlled temperature (22°C) and lighting (light on: 7 a.m.–
7 p.m.). After 1 week of acclimatization, rats were
individually housed and randomly distributed into two
groups and fed for 6 weeks with either a standard diet (by
energy 7.42% fat, 75% carbohydrates, 17.5% protein,
metabolized energy, 2.61 kcal/g) or a high-fat diet (by
energy 41% fat, 40% carbohydrates, 19% protein, metabo-
lized energy, 3.1 kcal/g; Ssniff RM/H, Ssniff Spezialdiaten,
Soest, Germany). Body weight and food intake were
recorded daily. Seven days prior to sacrifice, a glucose
tolerance test was performed after 4 h fasting. A glucose load
of 1.5 g/kg was administered i.p., and blood samples were
collected by tail nicking at 0, 15, 30, 60, 120, 180, and
240 min. Glycemia was recorded using Glucotrend Active
(Roche, Basel, Switzerland), and the glucose area under
curve (AUC) was calculated at 240 min. Unpaired Student’s t
test was used for group comparisons.
The animals were sacrificed using light isoflurane
anesthesia (Halocarbon Laboratories, River Edge, NJ,
USA) and rapid decapitation between 9 a.m. and 1 p.m.
Tissues were rapidly removed, freeze-clamped, and stored
at −80°C. All procedures were approved by the ethics
committees of the Universities of Geneva or Lausanne and
were in accordance with the Swiss guidelines for animal
experimentation.
cDNA cloning of the human klotho extracellular domain
Total human kidney RNA was used as the template for the
synthesis of first-strand complementary DNA (cDNA) using
ImProm-II Reverse Transcriptase (Promega, Dübendorf,
Switzerland) and oligo(dT) primers. PCR was performed
using GoTaq/Pfu DNA polymerase (Promega) according to
the manufacturer’s instructions with primers for amplifica-
tion of two overlapping cDNA fragments named A
(N-term: 2,095 bp) and B (C-term: 1,062 bp) covering the
whole coding sequence. These fragments were inserted into
pGem-T Easy vector. The B fragment was used as a
template to generate mutated fragments with the stop codon
(full-length) or the transmembrane domain (extracellular
domain) removed. Complete klotho full-length and extra-
cellular domain constructs carrying polyhistidine and myc
tags at the C-terminus were generated by three-piece
ligations into the pcDNA3.1 myc/his expression vector.
Full sequencing of the constructs (Microsynth, Balgach,
Switzerland) confirmed complete homology with the
published sequence (Genbank accession number
NM_004795.2). The klotho extracellular domain (KLEC)
construct consists of residues 1–982, followed by a short
four residues linker sequence and the polyhistidine and myc
tags.
Cell culture and transfection
HEK293 cells were grown in DMEM (Gibco, Invitrogen
Life Science, Carlsbad, CA, USA) supplemented with 10%
fetal calf serum (FCS) and 1% P/S (Penicillin Streptomy-
cin, Gibco). After transfection using TransIT-293 (Mirus),
cells stably expressing the klotho extracellular domain
(HEK-KLEC) were obtained by selection for 14 days in
medium supplemented with 0.5 mg/mL G418. Klotho
protein secreted into the conditioned medium of this cell
line was purified to near-homogeneity using the nickel–
agarose resin. The biological effects of klotho, either
contained in conditioned media or in purified form, were
tested on HEK293, rat L6, and human HepG2 cells. L6 and
HepG2 cells were grown in MEM-α and DMEM media,
respectively, supplemented with 10% FCS.
Western blot
Protein extracts were prepared from rat organs by mechan-
ical homogenization in radioimmunoprecipitation assay
buffer (NaCl 300 mM; Tris-HCl 100 mM; NP40 2%; SDS
0.2%; Deoxycholic acid 1%) with protease cocktail
inhibitor (set V, animal free Merck), 2 mM NaVO4 and
10 mM NaF. Cultured cells were directly solubilized in the
same buffer after three washes with phosphate-buffered
saline at 4°C. Total proteins were separated by standard
sodium dodecyl sulfate polyacrylamide gel electrophoresis
techniques and transferred to nitrocellulose membranes.
Proteins of interest were detected with specific primary
antibodies, horseradish peroxidase-conjugated secondary
antibodies, and an enhanced chemiluminescence detection
system (Amersham, Otelfingen, Switzerland). Proteins were
quantified using the ChemiDoc XRS from Bio-Rad (Bio-
Rad, Reinach, Switzerland) and Quantity One software
(Bio-Rad).
Real-time PCR
Total RNA was extracted from rat organs with Trizol
reagent (Invitrogen), and reverse transcription was made by
murine leukemia virus-R reverse transcriptase according to
the manufacturer’s protocol (Promega). Quantitative real-
time PCR (qPCR) was assessed in ABI Thermal Cycler
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apparatus with PRISM® 7500 Sequence Detection System
was programmed with the ABI standard cycling program of
50°C for 2 min, denaturation at 95°C for 2 min, 50 cycles
of primer annealing at 95°C for 15 s, and primer extension
at 60°C for 30 s. cDNA quantification was performed using
FastStart universal SYBR Green Master (Roche) according
to the manufacturer’s instructions. Rat klotho primers were
designed using ABI software (P1: 5′-TGGACCCACCTT
GAGTTTTCA-3′; P2: 5′-TTGCCTCAGGTTGGGAGATT-
3′). Klotho messenger RNA (mRNA) values were normal-
ized for cyclophilin mRNA used as a stable control.
Results
Klotho expression and tissue distribution in relation
to insulin resistance in rats
We first studied the klotho tissue distribution in rat organs
and tested whether it is modified by obesity/insulin
resistance in Zucker rats. Ten-week-old obese Zucker rats
(body weight 346.3± 8.0 g, mean±standard deviation (SD))
and control rats (284.5±9.2 g) were sacrificed, and various
organs were collected for RNA and protein extraction (n= 5
in each group). Klotho mRNA levels were analyzed by
quantitative RT-PCR (Fig. 1a). Klotho mRNA was readily
detected in kidneys. However, only low levels (<1.5%
relative to kidneys) were found in liver, white and red
muscle, epididymal white adipose tissue, and brain (frontal
lobe). Klotho mRNA levels were somewhat higher in the
hypothalamus (2.17± 1.07%, mean±standard error of the
mean (SEM)) than in the brain (0.4±0.15%), but
the difference failed to achieve statistical significance
(p=0.14 using unpaired Student’s t test). We found no
differences in klotho mRNA levels between obese Zucker
and control rats, neither in kidneys nor in other organs.
Klotho protein levels tested by Western blot were similar in
kidneys from obese Zucker and control rats (Fig. 1b).
We also tested klotho expression and tissue distribution
after high-fat feeding in Wistar rats, another model of insulin
resistance. Four-month-old Wistar rats were fed a high-fat or
control diet for 5 weeks prior to sacrifice (n=6 for each
group). High-fat feeding resulted in higher body weight
(379.3±6.1 g compared to 342.4±6.1 g in control rats, p<
0.002), higher fasting glucose level (6.0±0.2 mmol/l, versus
5.4 mmol/l in control rats, p<0.03), and a more pronounced
rise in blood glucose during a glucose tolerance test
(Fig. 2a), indicative of insulin resistance. Again, klotho
mRNA was readily detected in the kidney, but only at low
levels in inguinal and epidydimal white adipose tissue and
brain (Fig. 2b). Klotho mRNA was significantly higher (p<
0.001) in the hypothalamus (1.17±0.2%) and in the pituitary
(0.83±0.17%) than in the whole brain (frontal lobe; 0.23±
0.06%). However, these values were again much lower than
in the kidney. There was no significant change in klotho
mRNA levels after high-fat feeding, neither in the kidney nor
in other organs tested.
These findings indicate that renal klotho expression is
unchanged in two rat models of insulin resistance, arguing
against an obligatory role for regulated klotho expression in
the pathogenesis of insulin resistance. Further, the expres-
sion of klotho was restricted to the kidneys both in control
and insulin resistant animals.
Klotho kidney induction after 4 weeks treatment
with pioglitazone
While klotho expression was not regulated in our insulin
resistance models, it may be modulated by drugs that
modify insulin resistance. Some studies have suggested a
role of thiazolidinediones (glitazones) in the regulation of
renal klotho expression [17, 22]. We next investigated the
effects of glitazone treatment on renal klotho expression in
obese Zucker rats. Zucker fatty rats were treated for 4 weeks
with pioglitazone (see Methods). This treatment resulted in
significant weight gain (503±7 g compared to 450±12 g in
Fig. 1 Klotho tissue distribution in Zucker rats. a Klotho mRNA
levels were determined in rat organs from lean or obese (fa/fa) Zucker
rats by quantitative RT-PCR. Results are shown on a log scale in
arbitrary units, with a pool of renal total RNA defined as 100%. No
signal was detected in the absence of reverse transcriptase. Results are
shown as mean±SD, n=5. WATE epididymal white adipose tissue. b
Klotho protein was detected in protein extracts from rat kidneys by
Western blot. Mouse kidney homogenate (C57Bl6) was added as a
positive control. No differences in renal klotho expression were
observed either at the mRNA or the protein levels
468 Pflugers Arch - Eur J Physiol (2010) 459:465–473
control rats, mean±SEM, p<0.005). Insulin resistance was
markedly decreased, as shown by reduced insulinemia (2.4±
0.1 μU/ml compared to 24.6±4.2 μU/ml in obese untreated
rats, p<0.001) and HOMA-IR index (0.46±0.07 compared
to 7.30±1.81 in obese untreated rats, p< 0.008). In spite of
these metabolic differences, there were no significant differ-
ences in renal klotho expression in treated and untreated
animals, whether judged by mRNA levels (Fig. 3a) or
protein levels (Fig. 3b). These results do not confirm that
glitazone treatment increases renal klotho expression in
insulin-resistant rats.
Effects of klotho on FGF23 and IGF-1 signaling
in HEK293 cells
Circulating klotho may determine insulin sensitivity by
direct regulation of insulin and IGF-1 signaling [2]. Both
full-length and soluble klotho proteins are coactivators of
Fig. 2 Klotho tissue distribution in high-fat fed Wistar rats. a Wistar
rats were fed a high-fat or a control diet. High-fat feeding resulted in
glucose intolerance as judged by a higher glucose areas under the
curve (AUC; mean±SEM; n=5; *p=0.01, Student’s t test). b mRNA
expression was tested by quantitative RT-PCR in kidney, epididymal
white adipose tissue (WATE ), inguinal white adipose tissue (WATI),
brain (frontal lobe), hypothalamus, and pituitary. Results are shown on
a log scale in arbitrary units (mean±SD), with a pool of rat total
kidney RNA defined as 100%. Klotho expression was higher in
hypothalamus and pituitary than in the brain. There were no differ-
ences in klotho expression between high-fat fed and control animals
Fig. 3 Effect of pioglitazone treatment on renal klotho expression in
obese Zucker rats. Obese Zucker rats were treated for 4 weeks with
20 mg/ml/kg of pioglitazone. a Renal klotho expression was measured
by quantitative RT-PCR. Results are shown in arbitrary units, with a
pool of renal total RNA defined as 100%. b Renal klotho expression
was measured by Western blot in kidney protein extracts. The blot was
also revealed for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) to verify equal protein load. The bands were quantified
by densitometric scanning; results are shown in arbitrary units, the
mean value of the control group being defined as 100%. Pioglitazone
did not significantly modify renal klotho expression, neither at the
mRNA nor the protein level
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FGF23 in responsive cells [6, 7]. The klotho effects on
insulin signaling have been reported in the absence of
FGF23, pointing to a mechanism of action distinct from
FGF23 coactivation [2]. We next studied the effects of the
human klotho protein on both FGF23 and IGF-1 signaling.
The human klotho cDNA was cloned and inserted into a
eukaryotic expression vector to generate the extracellular
domain carrying myc and polyhistidine tags at the C-
terminus (KLEC, MW 116 kD). We next generated a
HEK293 cell line stably transfected with this construct
(HEK-KLEC). The KLEC protein was purified on nickel–
agarose columns. However, this purified protein failed to
inhibit insulin signaling in rat L6 cells, as judged by IRS-1
and Akt phosphorylation (not shown). It also failed to
coactivate FGF23 signaling in HEK293 cells. We suspected
that the purification procedure inactivated the protein and
therefore, returned to testing the bioactivity of conditioned
media from HEK-KLEC cells.
We first tested whether conditioned medium from HEK-
KLEC cells can coactivate FGF23 signaling, as judged by
FRS2-α (FGF receptor substrate 2-α) and ERK1/2 phos-
phorylation by Western blot (Fig. 4). Confluent HEK-
KLEC and control, wild-type HEK293 (HEK-WT) cells
were grown in serum-free medium. After 24 h, the
conditioned media were concentrated by ultrafiltration.
The estimated final klotho concentration (calculated from
the myc immunoreactivty compared to the purified protein)
was 10–30 nmol/l. In HEK-WT cells, FGF2 (used as a
positive control for FGFR1 activation) induced phosphor-
ylation of both FRS2-α and ERK1/2. As expected,
conditioned medium from HEK-KLEC had no effect when
added alone. However, the addition of FGF23 resulted in
activation of both FRS2-α and ERK1/2 when added
together with conditioned medium from HEK-KLEC but
not from HEK-WT cells (Fig. 4). These results confirm that
the klotho recombinant protein contained in HEK-KLEC-
conditioned media is an effective FGF23 coactivator in
HEK cells.
HEK cells respond to both FGF2 and IGF-1 in terms of
ERK phosphorylation. We next explored whether the
klotho protein inhibits IGF-1 signaling in HEK cells
(Fig. 5). Again, the conditioned medium from HEK-
KLEC but not from HEK-WT cells coactivated FGF23-
induced ERK1/2 phosphorylation. However, in the same
experiment, IGF-1-induced ERK1/2 phosphorylation was
not inhibited by HEK-KLEC-conditioned medium, com-
pared to HEK-WT-conditioned medium. Similar results
were obtained whether IGF-1 was tested at 10 or 100 nmol/l.
Thus, in the same cells, klotho coactivates FGF23 but fails to
inhibit IGF-1 signaling.
Effects of klotho protein on insulin signaling
We next reinvestigated whether the soluble klotho protein
modulates insulin signaling in insulin-responsive cell lines.
Confluent L6 cells were preincubated with fresh control
serum-free conditioned medium or conditioned medium
from HEK-KLEC or HEK-WT, prior to stimulation with
insulin or IGF-1 (Fig. 6). Both insulin (10 and 100 nmol/l)
Fig. 5 Effect of klotho FGF23 and IGF-1 signaling in HEK cells.
Conditioned media (CM) from wild-type HEK cells (HEK-WT) or
from HEK cells expressing soluble klotho (HEK-KLEC) or control
medium were concentrated by ultrafiltration and incubated with fresh
HEK cells for 2 h. FGF2 (100 ng/ml), FGF23 (100 ng/ml), and IGF-1
(100 nmol/l) were then added for 15 min as indicated. Cell lysates
were prepared for Western blots using antibodies against phospho-
ERK1/2 and total ERK1/2. A representative blot is shown. The bar
graphs show the quantification of band intensity (phosphorylated/total
protein ratio) of three independent experiments (mean±SEM) in
relative units, the value with FGF-2 (100 ng/ml) being defined as 100.
FGF2 but not FGF23 added alone induced ERK1/2 phosphorylation.
IGF-1-induced ERK1/2 phosphorylation was identical in CM from
HEK-KLEC and HEK-WT cells. However, FGF23-induced ERK1/2
phosphorylation was clearly higher when added to CM from HEK-
KLEC than from HEK-WT cells (p<0.05 by paired Student’s t test)
Fig. 4 Soluble klotho protein coactivates FGF23 signaling in HEK
cells. Conditioned media (CM) from wild-type HEK cells (HEK-WT)
or from HEK cells expressing soluble klotho (HEK-KLEC) or control
medium were concentrated by ultrafiltration and incubated with fresh
HEK cells for 2 h. FGF2 (100 ng/ml) and FGF23 (100 ng/ml) were
then added for 15 min as indicated. Cell lysates were then prepared for
Western blots using antibodies against Phospho-FRS-2α, phospho-
ERK1/2, and total ERK1/2. FGF2 stimulated both FRS-2α and
ERK1/2 phosphorylation as expected. FGF23 stimulated FRS-2α
and ERK1/2 phosphorylation only when added to HEK-KLEC but not
to HEK-WT-conditioned medium
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and IGF-1 (10 nmol/l) markedly increased Akt and ERK1/2
phosphorylation. In the presence of conditioned media, basal
Akt and ERK1/2 phosphorylation was somewhat increased,
presumably because of activation by nonspecific HEK cell-
derived factors. However, insulin- and IGF-1-induced Akt
and ERK1/2 phosphorylation was not significantly altered by
HEK-KLEC-conditioned medium, compared to HEK-WT-
conditioned medium (paired Student’s t test, n=3 indepen-
dent experiments). We observed a similar lack of inhibition
of insulin and IGF-1 signaling by HEK-KLEC-conditioned
medium in human HepG2 cells (not shown).
Discussion
Studies in Caenorhabditis elegans, Drosophila, and mice
have identified the insulin and/or IGF-1 receptors and
several downstream signaling molecules as aging genes
[23]. For instance, the heterozygous IGF-1 receptor
knockout mouse has an extended life span [24]. Similarly,
inactivation of the insulin receptor gene in adipose tissue is
also associated with an extended life span [25]. These
studies indicate that insulin and/or IGF-1 resistance is
associated with increased longevity. However, this notion
remains to be reconciled with the well-established role of
insulin resistance in the metabolic syndrome which under-
lies a risk for diabetes and cardiovascular disease. The
metabolic syndrome is a complex metabolic disorder, in
which insulin resistance can be seen as the consequence of
“fuel overload” leading to ectopic fat accumulation. It is,
therefore, conceivable that insulin resistance (in a biochem-
ical sense) antagonizes the pathogenesis of insulin resis-
tance understood as a clinical syndrome [26]. Studies on the
cellular mechanisms of action of klotho may contribute to
an understanding of this paradox.
Our data indicate that klotho is not regulated in two rat
models of insulin resistance, the obese Zucker rat and high-
fat feeding in Wistar rats. Decreased renal klotho expres-
sion was shown by Northern blot analysis in the OLETF
rat, a model of the metabolic syndrome [17]. Our data,
based on quantitative RT-PCR and Western blots, indicate
that reduced renal klotho expression is not a general feature
of insulin resistance in rodents. Previous studies have
suggested that treatment with glitazones increases renal
klotho expression. However, we failed to observe increased
renal klotho expression in obese Zucker rats treated with
pioglitazone, although this treatment markedly reduced
insulin resistance as expected. Transgenic mice overex-
pressing Klotho in a ubiquitous manner are characterized
by insulin resistance. Insulin resistance is possibly con-
ferred by klotho expression in insulin-sensitive tissues.
However, we found only low levels of extrarenal klotho
expression in liver, muscle, adipose tissue, and hypothala-
mus/pituitary, both in insulin resistant and control animals.
It is, therefore, unlikely that regulated extrarenal klotho
expression plays an important role in insulin resistance
syndromes. We, thus, found no evidence of regulated
klotho expression in insulin resistance or its treatment.
However, these data do not rule out that constitutively
expressed klotho plays a role in insulin resistance.
Soluble klotho protein has been identified in serum and
cerebrospinal fluid and may act as an endocrine factor. Our
experiments with purified klotho protein failed to identify
any klotho bioactivity. However, conditioned media from
cells expressing the klotho protein were also unable to
inhibit IGF-1 signaling in HEK cells, although they
successfully coactivated FGF23, indicating that the klotho
protein in conditioned media is bioactive. Further, klotho-
containing media failed to inhibit IGF-1 and insulin
signaling in rat L6 and human HepG2 cells. Our results
Fig. 6 Effect of klotho on IGF-1 and insulin signaling in L6 cells.
Conditioned media (CM) from wild-type HEK cells (HEK-WT) or
from HEK cells expressing soluble klotho (HEK-KLEC) or control
medium (Ctrl) were concentrated by ultrafiltration and incubated with
L6 cells for 2 h. Insulin (Ins) and IGF-1 were then added for 10 min.
Cell lysates were prepared for Western blots using antibodies against
phosphor-Akt, total Akt, phospho-ERK1/2, and total ERK1/2.
Representative Western blots are shown. The corresponding bar
graphs show the quantification of band intensity (phosphorylated/
total protein ratio) of three independent experiments (mean±SEM) in
relative units, the value with insulin 100 nmol/l being defined as 100.
Both insulin and IGF-1 induced Akt and ERK1/2 phosphorylation, an
effect that was not significantly altered by HEK-KLEC-CM compared
to HEK-WT-CM
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stand in contrast with the data published by Kurosu et al.
[2], who showed potent inhibition of insulin and IGF-1
signaling by purified murine recombinant klotho protein in
L6 cells. These discrepancies may be due to inactivation of
klotho bioactivity during our purification procedure (using
a technique different from the one used by Kurosu et al.) or
to species restrictions. However, since klotho-containing
conditioned media coactivate FGF23 as previously de-
scribed, the absence of inhibition of IGF-1 signaling
(shown within the same experiment) cannot be attributed
to the lack of klotho bioactivity. Further, klotho-containing
media failed to inhibit insulin and IGF-1 signaling in both
rat L6 and human HepG2 insulin-sensitive cells, arguing
against a problem of species restriction. We cannot formally
rule out the possibility that higher klotho protein concen-
trations or multiple repeat experiments might have uncov-
ered minor effects of soluble klotho on insulin or IGF-1
signaling. However, again, the klotho protein concentration
in the HEK-KLEC-conditioned medium we used was
sufficient for effective FGF23 coactivation. Our finding
that native, bioactive klotho protein fails to inhibit insulin
signaling raises the possibility that the direct effect of
purified klotho on insulin signaling observed by Kurosu et
al. results from a purification artifact. Our data certainly
indicate that klotho’s molecular determinants for klotho-
induced FGF23 coactivation and potential inhibition of
insulin and IGF-1 signaling are distinct.
Taken together, our data indicate that regulated klotho
expression (whether at the renal or extrarenal level) is not a
general feature of insulin resistance syndromes. They
further indicate that soluble klotho protein is not a direct
regulator of insulin signaling in at least two insulin-
sensitive cell lines. However, the hypothesis that klotho
exerts indirect effects on insulin sensitivity remains to be
investigated. As a FGF23 coactivator, klotho is involved in
calcium, phosphate, and vitamin D metabolism. Klotho-
deficient and FGF23 (−/−) mice are both characterized by
hypoglycemia and increased insulin sensitivity [1, 10, 15],
suggesting that the FGF23 axis is involved in the regulation
of insulin sensitivity. FGF23 inhibits vitamin D and PTH
synthesis and promotes renal phosphate excretion. Vitamin
D deficiency is associated with impaired insulin secretion
and corrected by vitamin D repletion [27]. Further, 25(OH)
vitamin D levels are inversely correlated with the preva-
lence of the metabolic syndrome [28]. However, klotho
mice display high insulin sensitivity and reduced insulin
secretion even though vitamin D levels are markedly
elevated. Phosphate depletion is thought to induce insulin
resistance. Insulin resistance is associated with low serum
phosphate in a population study on nondiabetic individuals
[29]. The prevalence of type 2 diabetes or impaired glucose
tolerance is elevated in primary hyperparathyroidism, possi-
bly via hypophosphatemia [30, 31]. It is, therefore, possible
that klotho/FGF23-induced renal phosphate excretion or
related changes play a role in the pathogenesis of insulin
resistance, a hypothesis that remains to be investigated.
A role for klotho in the aging process was originally
suspected by the reduced life span and phenotypic features
(including skin atrophy, osteoporosis, and arteriosclerosis)
in klotho mice [1]. These abnormalities can now largely be
attributed to the loss of FGF23 function and consequent
changes in calcium, phosphate, and vitamin D metabolism
[11]. However, the extended life span of klotho transgenic
mice remains to be explained. FGF23 gain-of-function
mutations result in congenital hypophosphatemic rickets [8,
9], i.e., a disease state. However, is it conceivable that the
weaker stimulation of FGF23 bioactivity afforded by klotho
overexpression results in extended life span, without
causing hypophosphatemia or bone disease. Such an effect
may be associated with (or even mediated by) insulin
resistance indirectly induced by hypophosphatemia or other
FGF23 biological effects, as discussed above. Further, Liu
et al. have suggested that Wnt signaling is involved stem
cell depletion. Klotho may directly inhibit Wnt signaling,
thereby preserving stem cell function [32]. The relative
roles of FGF23 signaling, insulin resistance, and Wnt
signaling in the extended life span seen with klotho
overexpression remain to be established.
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